Screener
Ionis Pharmaceuticals IONS Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued liabilities | 115,778 | 106,089 |
| Income taxes payable | 2,877 | 2,713 |
| 0 percent convertible senior notes due April 2026, net | - | 431,948 |
| Current portion of deferred contract revenue | 73,837 | 73,761 |
| Other current liabilities | 25,149 | 22,738 |
| Total current liabilities | 315,638 | 781,567 |
| Long-term deferred contract revenue | 63,030 | 92,001 |
| 0 percent convertible senior notes due 2030, net | 753,356 | 751,495 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's deferred revenue?
- Ionis Pharmaceuticals (IONS) reported deferred revenue of $73.84M in Q2 2026.
- How has Ionis Pharmaceuticals's deferred revenue changed year-over-year?
- Ionis Pharmaceuticals's deferred revenue decreased by 2.7% year-over-year, from $75.91M to $73.84M.
- What is the long-term trend for Ionis Pharmaceuticals's deferred revenue?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's deferred revenue has grown at a -7.4% compound annual growth rate (CAGR), from $108.38M to $73.76M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Ionis Pharmaceuticals's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude